Lytle B W, Priest B P, Taylor P C, Loop F D, Sapp S K, Stewart R W, McCarthy P M, Muehrcke D, Cosgrove D M
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, OH 44195, USA.
J Thorac Cardiovasc Surg. 1996 Jan;111(1):198-207; discussion 207-10. doi: 10.1016/S0022-5223(96)70417-8.
From 1975 through 1992, we reoperated on 146 patients for the treatment of prosthetic valve endocarditis. Prosthetic valve endocarditis was considered to be early (< 1 year after operation) in 46 cases and active in 103 cases. The extent of the infection was prosthesis only in 66 patients, anulus in 46, and cardiac invasion in 34. Surgical techniques evolved in the direction of increasingly radical débridement of infected tissue and reconstruction with biologic materials. All patients were treated with prolonged postoperative antibiotic therapy. There were 19 (13%) in-hospital deaths. Univariate analyses demonstrated trends toward increasing risk for patients with active endocarditis and extension of infection beyond the prosthesis; however, the only variables with a significant (p < 0.05) association with increased in-hospital mortality confirmed with multivariate testing were impaired left ventricular function, preoperative heart block, coronary artery disease, and culture of organisms from the surgical specimen. During the study period, mortality decreased from 20% (1975 to 1984) to 10% (1984 to 1992). For hospital survivors the mean length of stay was 25 days. Follow-up (mean interval 62 months) documented a late survival of 82% at 5 postoperative years and 60% at 10 years. Older age was the only factor associated (p = 0.006) with late death. Nineteen patients needed at least one further operation; reoperation-free survival was 75% at 5 and 50% at 10 postoperative years. Fever in the immediate preoperative period was the only factor associated with decreased late reoperation-free survival (p = 0.032). Prosthetic valve endocarditis remains a serious complication of valve replacement, but the in-hospital mortality of reoperations for prosthetic valve endocarditis has declined. With extensive débridement of infected tissue and postoperative antibiotic therapy, the extent and activity of prosthetic valve endocarditis does not appear to have a major impact on late outcome, and the majority of patients with this complication survive for 10 years after the operation.
1975年至1992年期间,我们对146例人工瓣膜心内膜炎患者进行了再次手术治疗。人工瓣膜心内膜炎被认为是早期(术后<1年)的有46例,活动期的有103例。感染范围仅累及人工瓣膜的有66例,累及瓣环的有46例,累及心脏的有34例。手术技术朝着对感染组织进行更彻底清创以及使用生物材料重建的方向发展。所有患者术后均接受了长时间的抗生素治疗。有19例(13%)患者在住院期间死亡。单因素分析显示,活动期心内膜炎患者以及感染超出人工瓣膜范围的患者风险有增加趋势;然而,多因素检验证实与住院死亡率增加有显著(p<0.05)关联的唯一变量是左心室功能受损、术前心脏传导阻滞、冠状动脉疾病以及手术标本的微生物培养结果。在研究期间,死亡率从20%(1975年至1984年)降至10%(1984年至1992年)。对于住院幸存者,平均住院时间为25天。随访(平均间隔62个月)显示,术后5年的晚期生存率为82%,10年时为60%。年龄较大是与晚期死亡相关的唯一因素(p = 0.006)。19例患者至少需要再次进行一次手术;术后5年无再次手术生存率为75%,10年时为50%。术前即刻发热是与晚期无再次手术生存率降低相关的唯一因素(p = 0.032)。人工瓣膜心内膜炎仍然是瓣膜置换的严重并发症,但人工瓣膜心内膜炎再次手术的住院死亡率有所下降。通过对感染组织进行广泛清创和术后抗生素治疗,人工瓣膜心内膜炎的范围和活动程度似乎对晚期结局没有重大影响,并且大多数患有这种并发症的患者在手术后存活10年。